Skip to main content
. 2013 Dec 6;3(12):e167. doi: 10.1038/bcj.2013.64

Figure 5.

Figure 5

The chemical chaperone 4-PBA augments the effects of HSP90 and IBP inhibition on monoclonal protein trafficking and induction of the UPR. (a) RPMI-8226 and ALMC-2 cells were treated with 10 μM lovastatin (Lov), 0.5 μM 17-AAG (AAG) and/or 0.5 mM 4-PBA (PBA) for 48 h. Intracellular lambda light chain levels were measured via ELISA. Data are expressed as percentage of control untreated cells (mean±s.d., n=3) and are representative of three independent experiments. The * denotes P <0.05 per unpaired two-tailed t-test and compares treatments with and without 4-PBA. (b) Real-time PCR was performed using primers for PERK, ATF6, IRE1 and GADD153 following incubation of RPMI-8226, U266 or ALMC-2 cells with 10 μM lovastatin (Lov) and/or 0.5 mM 4-PBA (PBA) for 48 h. Data were normalized to β-actin levels and are expressed as relative to control untreated cells (mean±s.d., n=3). Data are representative of two independent experiments. The * denotes P <0.05 per unpaired two-tailed t-test and compares treated cells with control cells. The # denotes P <0.05 for the combination of lovastatin and 4-PBA compared with lovastatin alone.